FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 293 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival... January 25, 2022 6 highlights from our Black in Cancer conference October 31, 2022 What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story ScottishPower supports vital research into air pollution and cancer
